Abstract
The non-small cell lung cancer treatment showed great progress with the 3rd generation drugs introduction in the 90-ies, however standard cytostatic treatment does not show and further significant treatment results improvement and most probably has reached its potentialities border. New drugs are introduced into clinical practice in this decade, sometimes called 4th generation drugs, with mechanism of action aiming in principle at signal pathways and enabling targeted biologic treatment.
Well studied and proven in clinical practice target of biological treatment are EGFR (epidermal growth factor receptor) and angioneogenesis process regulating molecules - angiogenesis inhibitors. Erlotinib and bevacizumab are currently registered for non-small cell lung cancer treatment in the EU.
Other substances are in different phases of clinical research or in front of registration procedure.